表紙
市場調査レポート

プロテオミクス:技術と世界市場

Proteomics: Technologies and Global Markets

発行 BCC Research 商品コード 92659
出版日 ページ情報 英文 223 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
プロテオミクス:技術と世界市場 Proteomics: Technologies and Global Markets
出版日: 2015年02月23日 ページ情報: 英文 223 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

当レポートでは、世界のプロテオミクス市場における技術、データベース・ソフトウェア市場、装置市場、アプリケーション市場およびサービス市場を対象に調査分析し、実績データ・CAGR予測を用いた世界市場の動向分析、動向と機会、ベストセラー製品、主要企業、および競合展望の分析、包括的な企業プロファイルなどをお届けします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • プロテオミクス技術
  • レポートの範囲
  • プロテオミクス市場
  • プロテオミクス産業の成長促進因子
  • プロテオミクス産業

第4章 プロテオミクス技術

  • 技術プラットフォームのイントロダクション
  • 質量分析ベースのプロテオミクス技術
  • バイオチップベースのプロテオミクス技術
  • 多重化プロテオミクスシステム
  • プロテオゲノミクス
  • プロテオミクス技術の進歩

第5章 創薬・薬剤開発におけるプロテオミクスのアプリケーション

  • 標的発見
  • リード特定
  • リード最適化
  • 前臨床研究

第6章 プロテオミクスの科学的イニシアチブ

第7章 臨床的プロテオミクスアプリケーション

  • 癌アプリケーション
  • 感染症
  • 糖尿病
  • 神経疾患
  • 免疫疾患
  • 循環器疾患
  • 子癇前症

第8章 プロテオミクス産業

  • 買収
  • 戦略的アライアンス
  • 質量分析産業
  • プロテオミクスクロマトグラフィー産業
  • プロテオミクスベースの創薬・薬剤開発産業
  • プロテオミクスバイオチップ産業
  • 抗体試薬産業
  • 多重タンパク質診断産業

第9章 プロテオミクス市場

  • プロテオミクス産業成長の促進因子
  • 世界のプロテオミクス市場

第10章 プロテオミクス特許

  • バイオチップ特許
  • 質量分析特許

第11章 企業プロファイル

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO034D

The global proteomics market was valued at nearly $5.1 billion in 2014 and is growing at a compound annual growth rate (CAGR) of 18.0% to reach a forecast value of $11.6 billion by 2019.

This report provides:

  • An overview of the global proteomics market, which covers: technologies, database and software markets, equipment markets, application markets and service markets.
  • Analyses of global market trends, with data from 2013 and 2014, and projections of CAGRs through 2019.
  • Discussion of trends and opportunities, top-selling products, key players, and a competitive outlook.
  • Comprehensive company profiles across subsegments, such as protein chip providers, reagent providers, service providers, informatics and database providers, etc.

image1

REPORT SCOPE

SCOPE AND FORMAT

The study scope covers MS instruments, consumables, workflow products, planar arrays, bead arrays and LOAC. It also covers the research, drug discovery and development, diagnostics and applied end-user market segments. The main geographical markets-North America, Europe, Asia and Rest of World (ROW)-are included.

The MS market is covered by instrument type, MS consumables, product type and end-user markets. The biochip market is covered by biochip type and the end-user market for each type. The diagnostics market is covered in some detail, including by major platform (i.e., MS, biochips), by disease type and for cancer by indication. This report provides the current market sizes for these segments, as well as their forecasted growth through 2019. Technology status and market driving forces are discussed and analyzed. Factors that influence each market are also highlighted, including growth-driving forces, industry alliances and acquisitions, applications in diagnostics and drug discovery, customer needs and competitive trends.

Key industry acquisitions and strategic alliances are given for the three-year period from 2012 through 2014.

This report also examines the main patent trends within the industry and profiles 108 proteomics companies.

ANALYST'S CREDENTIALS

John Bergin is the author of previous BCC Research biotechnology reports titled Next Generation Sequencing: Emerging Clinical Applications and Global Markets; Agricultural Biotechnology: Emerging Technologies and Global Markets; Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; DNA Sequencing: Emerging Technologies and Applications; Biologic Imaging Reagents: Technologies and Global Markets; and Synthetic Biology: Emerging Global Markets.

Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with a separations technology company. Mr. Bergin holds a BS degree in Chemistry, an MS degree in Biotechnology and a Master of Business Administration.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE
  • SCOPE AND FORMAT
  • METHODOLOGY
  • INFORMATION SOURCES
  • RELATED BCC RESEARCH REPORTS
  • ANALYST'S CREDENTIALS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL PROTEOMIC MARKET BY END-USER INDUSTRY, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL PROTEOMIC MARKET BY END-USER INDUSTRY, 2013-2019 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • PROTEOMIC TECHNOLOGIES
  • TABLE 1 ARRAY VERSUS LOAC BIOCHIPS
  • SCOPE OF REPORT
  • TABLE 2 SCOPE OF REPORT
  • PROTEOMICS MARKET 1
  • TABLE 3 GLOBAL PROTEOMIC MARKET BY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • DRIVING FORCES FOR PROTEOMICS INDUSTRY GROWTH
  • TABLE 4 PROTEOMIC INDUSTRY GROWTH DRIVING FORCES
  • THE PROTEOMICS INDUSTRY
  • TABLE 5 BIOCHIP INDUSTRY COMPARISONS

CHAPTER 4 PROTEOMICS TECHNOLOGIES

  • INTRODUCTION TO TECHNOLOGY PLATFORMS
  • FIGURE 1 MASS SPECTROMETRY GENERALIZED WORKFLOW SCHEMATIC
  • FIGURE 2 PROTEOMIC BIOCHIP AND ARRAY FORMATS
  • MS-BASED PROTEOMICS TECHNOLOGIES
    • SAMPLE PREPARATION ASSAYS
    • TAGGING/AFFINITY METHODS
    • MS INSTRUMENTS AND CONSUMABLES
    • TABLE 6 MASS SPECTROMETER PLATFORMS
  • BIOCHIP-BASED PROTEOMICS TECHNOLOGIES
  • TABLE 7 BIOCHIP-BASED PROTEOMIC TECHNOLOGIES
  • TABLE 8 PLANAR-BASED VERSUS BEAD-BASED ARRAYS
  • MULTIPLEX PROTEOMICS SYSTEMS
  • TABLE 9 ADVANTAGES OF MULTIPLEXING FOR DIAGNOSTICS
  • PROTEOGENOMICS
  • RECENT ADVANCES IN PROTEOMIC TECHNOLOGIES
  • TABLE 10 TECHNICAL ADVANCES IN PROTEOMICS

CHAPTER 5 PROTEOMIC APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT

  • TABLE 11 PROTEOMIC APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT
  • TARGET DISCOVERY
  • LEAD IDENTIFICATION
  • LEAD OPTIMIZATION
  • PRECLINICAL STUDIES

CHAPTER 6 PROTEOMICS SCIENTIFIC INITIATIVES

  • TABLE 12 LARGE-SCALE PROTEOMIC INITIATIVES

CHAPTER 7 CLINICAL PROTEOMICS APPLICATIONS

  • TABLE 13 STRATEGIES FOR OVERCOMING HIGH-ABUNDANCE PROTEINS IN CLINICAL SAMPLES
  • CANCER APPLICATIONS
    • CANCER OVERVIEW
    • TABLE 14 ESTIMATED U.S. INCIDENCE AND DEATHS FOR SELECTED CANCERS, 2010 AND 2013
      • Bladder Cancer
      • TABLE 15 STATUS OF BLADDER CANCER NEXT GENERATION DIAGNOSTICS TESTS
      • Breast Cancer
        • Breast Cancer Screening
        • Prognosis and Pharmacogenetics Tests
        • TABLE 16 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION
        • Breast Cancer MDx Platforms
        • TABLE 17 BREAST CANCER MDX TECHNOLOGY PLATFORMS
        • Status of Next Generation Breast Cancer Tests
        • TABLE 18 STATUS OF NEXT GENERATION BREAST CANCER TESTS
        • Breast Cancer Early Detection/Screening Tests
        • Breast Cancer Risk Tests
        • Response to Chemotherapy; Recurrence Probability; Subtyping
      • Colorectal Cancer
      • Gastric Cancer
      • TABLE 19 STATUS OF GASTRIC/STOMACH CANCER NEXT GENERATION DIAGNOSTICS TESTS
      • Kidney Cancer
      • TABLE 20 STATUS OF KIDNEY CANCER NEXT GENERATION DIAGNOSTICS TESTS
      • Lung Cancer
      • TABLE 21 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER (%)
      • TABLE 22 STATUS OF LUNG CANCER NEXT GENERATION DIAGNOSTICS TESTS
      • Lymphomas
      • TABLE 23 STATUS OF LYMPHOMA CANCER NEXT GENERATION DIAGNOSTICS TESTS
      • Ovarian Cancer
      • TABLE 24 EARLY SCREENING OVARIAN CANCER TESTS
      • TABLE 25 STATUS OF OVARIAN CANCER NEXT GENERATION DIAGNOSTICS TESTS
      • Pan-Cancer
      • TABLE 26 STATUS OF PAN-CANCER NEXT GENERATION DIAGNOSTICS TESTS
      • Prostate Cancer
      • TABLE 27 STATUS OF PROSTATE CANCER NEXT GENERATION DIAGNOSTICS TESTS
      • Thyroid Cancer
      • TABLE 28 STATUS OF THYROID CANCER NEXT GENERATION DIAGNOSTICS TESTS
  • INFECTIOUS DISEASES
  • DIABETES
  • NEUROLOGICAL DISORDERS
    • ALZHEIMER'S DISEASE 7
    • TABLE 29 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES
    • SCHIZOPHRENIA
  • IMMUNE DISEASES
    • HLA TYPING
    • AUTOIMMUNE DISEASE
    • TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET
  • CARDIOVASCULAR DISEASE
  • PREECLAMPSIA
  • TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS

CHAPTER 8 PROTEOMICS INDUSTRY

  • INDUSTRY ACQUISITIONS
  • TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014
  • INDUSTRY STRATEGIC ALLIANCES
  • TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014
  • MASS SPECTROMETRY INDUSTRY
  • TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS
  • TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES
  • TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES
  • CHROMATOGRAPHY INDUSTRY
  • FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW
  • TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES
  • TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES
  • PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY
  • TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY
  • PROTEOMICS BIOCHIP INDUSTRIES
    • PEPTIDE MICROARRAY INDUSTRY
    • TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES
    • HIGH DENSITY PROTEIN ARRAY INDUSTRY
    • TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES
    • ANTIBODY MICROARRAY INDUSTRY
    • TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES
    • CHINA'S BIOCHIP INDUSTRY
    • TABLE 43 CHINA'S BIOCHIP INDUSTRY
    • LOAC PROTEOMICS INDUSTRY
    • TABLE 44 LOAC COMPETITOR LANDSCAPE
  • CHEMICAL PROTEOMICS INDUSTRY
  • ANTIBODY REAGENT INDUSTRY
  • TABLE 45 ANTIBODY REAGENT MARKET, 2014 (%)
  • MULTIPLEX PROTEIN DIAGNOSTICS INDUSTRY
  • TABLE 46 MULTIPLEX PROTEIN IN-VITRO DIAGNOSTICS COMPANIES
  • DRIED BLOOD SPOTTING PROTEOMICS INDUSTRY
  • TABLE 47 DRIED BLOOD SPOT PROTEOMICS INDUSTRY
  • SINGLE CELL PROTEOMICS INDUSTRY
  • TABLE 48 SINGLE CELL PROTEOMICS INDUSTRY

CHAPTER 9 PROTEOMICS MARKETS

  • DRIVING FORCES OF PROTEOMICS INDUSTRY GROWTH
  • TABLE 49 PROTEOMIC INDUSTRY GROWTH DRIVING FORCES
  • GLOBAL PROTEOMICS MARKETS
    • MARKET SUMMARY
    • TABLE 50 GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2019 ($ MILLIONS)
    • RESEARCH MARKET
    • TABLE 51 GLOBAL PROTEOMIC RESEARCH MARKET BY PLATFORM, THROUGH 2019 ($ MILLIONS)
    • TABLE 52 GLOBAL PROTEOMIC RESEARCH MARKET BY BIOCHIP PLATFORM, THROUGH 2019 ($ MILLIONS)
    • DRUG DISCOVERY AND DEVELOPMENT MARKETS
    • TABLE 53 GLOBAL PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT PRODUCT MARKET BY PLATFORM, THROUGH 2019 ($ MILLIONS)
    • TABLE 54 GLOBAL PROTEOMIC BIOCHIP DRUG DISCOVERY AND DEVELOPMENT MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
    • PROTEOMICS DIAGNOSTIC MARKET
    • TABLE 55 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY PLATFORM, THROUGH 2019 ($ MILLIONS)
    • TABLE 56 GLOBAL BIOCHIP DIAGNOSTIC MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 57 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY DISEASE TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 58 STATUS OF PROTEOMIC-BASED DIAGNOSTICS FOR DIABETES, NEUROLOGICAL, AUTOIMMUNE, INFECTIOUS DISEASE, HLA TYPING, AND CARDIOVASCULAR DISEASE APPLICATIONS
    • TABLE 59 SEPSIS DIAGNOSTICS INDUSTRY
    • TABLE 60 GLOBAL PROTEOMIC CANCER DIAGNOSTIC PRODUCT MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • MASS SPECTROMETRY-BASED PROTEOMIC MARKET
    • TABLE 61 GLOBAL MASS SPECTROMETRY MARKET BY PRODUCT TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 62 GLOBAL MASS SPECTROMETRY MARKET BY END-USER INDUSTRY, THROUGH 2019 ($ MILLIONS)
      • MS-Based Clinical Diagnostics Markets
      • MS Clinical Platforms
    • TABLE 63 MRM-MS VERSUS MALDI MS IN CLINICAL APPLICATIONS
    • TABLE 64 MS CLINICAL INDUSTRY
    • TABLE 65 PHOSPHOPROTEOMICS PLATFORMS FOR CANCER APPLICATIONS
    • TABLE 66 GLOBAL MASS SPECTROMETRY INSTRUMENT PROTEOMICS MARKET BY TECHNIQUE, THROUGH 2019 ($ MILLIONS)
    • TABLE 67 GLOBAL MASS SPECTROMETRY CONSUMABLE MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
    • BIOCHIP-BASED PROTEOMICS MARKET
    • TABLE 68 GLOBAL PROTEOMIC BIOCHIP MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 69 GLOBAL PROTEOMIC ARRAY MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 70 GLOBAL PROTEOMIC BIOCHIP MARKET BY END-USER INDUSTRY, THROUGH 2019 ($ MILLIONS)
    • TABLE 71 GLOBAL PROTEOMIC ARRAY MARKET BY END-USER INDUSTRY, THROUGH 2019 ($ MILLIONS)
    • TABLE 72 GLOBAL PROTEOMIC LOAC MARKET BY END-USER INDUSTRY, THROUGH 2019 ($ MILLIONS)
    • PROTEOMICS GEOGRAPHIC MARKET
    • TABLE 73 GLOBAL PROTEOMIC MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 74 GLOBAL PROTEOMIC DIAGNOSTIC MARKET BY REGION, THROUGH 2019 ($ MILLIONS)

CHAPTER 10 PROTEOMICS PATENTS

  • BIOCHIP PATENTS
    • PROTEIN ARRAY PATENTS
    • TABLE 75 ARRAY-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014
    • LAB-ON-A-CHIP PATENTS
    • TABLE 76 LAB-ON-A-CHIP-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014
  • MASS SPECTROMETRY PATENTS
  • TABLE 77 MASS SPECTROMETRY-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014 (NO. OF PATENTS)

CHAPTER 11 COMPANY PROFILES

  • ABCODIA LTD.
  • ABLYNX NV
  • ACTIVIOMICS LTD.
  • ACTIVX BIOSCIENCES INC.
  • ADVANCED PROTEOME THERAPEUTICS INC.
  • AGILENT TECHNOLOGIES INC.
  • APPLIED MICROARRAYS
  • APPLIED PROTEOMICS
  • ARRAYIT CORP.
  • ASTUTE MEDICAL INC.
  • AVACTA GROUP PLC
  • AYOXXA BIOSYSTEMS GMBH
  • BIOCARTIS NV
  • BIODESIX INC.
  • BIOGNOSYS AG
  • BIOMERIEUX SA
  • BIOPROXIMITY LLC
  • BIO-RAD LABORATORIES INC.
  • BIO-TECHNE INC.
  • BRUKER CORP.
  • CAMBRIDGE PROTEIN ARRAYS LTD.
  • CAPRION PROTEOME INC.
  • CAPROTEC BIOANALYTICS GMBH
  • CARMENTA BIOSCIENCE INC.
  • CDI LABORATORIES INC.
  • CRELUX GMBH
  • CRESCENDO BIOSCIENCE
  • CRYSTALGENOMICS INC.
  • CYVEK INC.
  • DANAHER CORP.
  • DIASSESS
  • DIGILAB INC.
  • EPICYPHER INC.
  • EVOTEC AG
  • FLUIDIGM CORP
  • GENERAL ELECTRIC CO.
  • GLAXOSMITHKLINE PLC
  • GLOBAL DISCOVERY BIOSCIENCES
  • GL SCIENCES INC.
  • HEALTHTELL INC.
  • HYBRIGENICS SA
  • TABLE 78 APPLICATIONS FOR Y2H AND YCHEMH PROTEOMICS PLATFORMS
  • IMMUNOVIA AB
  • IMTAKT CORP.
  • INTEGRATED DIAGNOSTICS
  • INDI MOLECULAR
  • IRIS INTERNATIONAL INC.
  • LABCYTE INC.
  • LEAP TECHNOLOGIES INC.
  • LUMINEX CORP.
  • MERCK & CO. INC.
  • MERCK KGAA
  • MICROLYTIC
  • MRM PROTEOMICS INC.
  • MOSAIQUES DIAGNOSTICS AND THERAPEUTICS AG
  • MYCARTIS
  • MYRIAD GENETICS INC.
  • NEWOMICS INC.
  • NIRMIDAS BIOTECH INC.
  • OLINK BIOSCIENCE
  • ONCOPLEX DIAGNOSTICS
  • OPKO HEALTH INC.
  • PERKINELMER INC.
  • PERSONALIZED CANCER THERAPY INC.
  • PFIZER INC.
  • PHENOMENEX INC.
  • PHYLOGICA LTD.
  • PRESSURE BIOSCIENCES INC.
  • PROMETIC LIFE SCIENCES INC.
  • PROTAGEN AG
  • PROTEA BIOSCIENCES INC.
  • PROTEOCYTE DIAGNOSTICS INC.
  • PROTEOGENIX
  • PROTEOME SCIENCES PLC
  • PROTEOMICS INTERNATIONAL PTY LTD
  • PROTEOVISTA LLC
  • PROVISTA DIAGNOSTICS INC.
  • QIAGEN NV
  • QUANSYS BIOSCIENCES
  • QUANTERIX INC.
  • QUEST DIAGNOSTICS INC.
  • REPLIGEN CORP.
  • RETROGENIX LTD.
  • SAMDI TECH INC.
  • SERA PROGNOSTICS
  • SHIMADZU CORP.
  • SHISEIDO COMPANY LTD.
  • SHOWA DENKO KK
  • SIGMA ALDRICH
  • SINGULEX INC.
  • SISCAPA ASSAY TECHNOLOGIES INC.
  • SOMALOGIC INC.
  • TABLE 79 SOMALOGIC PROTEOMIC METHODS
  • SPHERE FLUIDICS LTD.
  • SPOTON CLINICAL DIAGNOSTICS LIMITED
  • SQI DIAGNOSTICS
  • SYNAGEVA BIOPHARMA
  • T2 BIOSYSTEMS
  • TALKING20 INC.
  • TABLE 80 PERSONALIZED PROTEOMICS COMPANIES
  • THERANOSTICS HEALTH
  • THERMO FISHER SCIENTIFIC INC.
  • THORNE DIAGNOSTICS INC.
  • TOSOH CORP.
  • UNIVERSAL BIOSENSORS LTD.
  • TABLE 81 UNIVERSAL BIOSENSORS DIAGNOSTIC PIPELINE
  • VERMILLION INC.
  • VG LIFE SCIENCES INC.
  • WATERS CORP.
  • XENCOR INC.
  • YMC CO. LTD.
  • ZEPHYRUS BIOSCIENCES INC.

LIST OF TABLES

  • SUMMARY TABLE GLOBAL PROTEOMIC MARKET BY END-USER INDUSTRY, THROUGH 2019 ($ MILLIONS)
  • TABLE 1 ARRAY VERSUS LOAC BIOCHIPS
  • TABLE 2 SCOPE OF REPORT
  • TABLE 3 GLOBAL PROTEOMIC MARKET BY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • TABLE 4 PROTEOMIC INDUSTRY GROWTH DRIVING FORCES
  • TABLE 5 BIOCHIP INDUSTRY COMPARISONS
  • TABLE 6 MASS SPECTROMETER PLATFORMS
  • TABLE 7 BIOCHIP-BASED PROTEOMIC TECHNOLOGIES
  • TABLE 8 PLANAR-BASED VERSUS BEAD-BASED ARRAYS
  • TABLE 9 ADVANTAGES OF MULTIPLEXING FOR DIAGNOSTICS
  • TABLE 10 TECHNICAL ADVANCES IN PROTEOMICS
  • TABLE 11 PROTEOMIC APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT
  • TABLE 12 LARGE-SCALE PROTEOMIC INITIATIVES
  • TABLE 13 STRATEGIES FOR OVERCOMING HIGH-ABUNDANCE PROTEINS IN CLINICAL SAMPLES
  • TABLE 14 ESTIMATED U.S. INCIDENCE AND DEATHS FOR SELECTED CANCERS, 2010 AND 2013
  • TABLE 15 STATUS OF BLADDER CANCER NEXT GENERATION DIAGNOSTICS TESTS
  • TABLE 16 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION
  • TABLE 17 BREAST CANCER MDX TECHNOLOGY PLATFORMS
  • TABLE 18 STATUS OF NEXT GENERATION BREAST CANCER TESTS
  • TABLE 19 STATUS OF GASTRIC/STOMACH CANCER NEXT GENERATION DIAGNOSTICS TESTS
  • TABLE 20 STATUS OF KIDNEY CANCER NEXT GENERATION DIAGNOSTICS TESTS
  • TABLE 21 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER (%)
  • TABLE 22 STATUS OF LUNG CANCER NEXT GENERATION DIAGNOSTICS TESTS
  • TABLE 23 STATUS OF LYMPHOMA CANCER NEXT GENERATION DIAGNOSTICS TESTS
  • TABLE 24 EARLY SCREENING OVARIAN CANCER TESTS
  • TABLE 25 STATUS OF OVARIAN CANCER NEXT GENERATION DIAGNOSTICS TESTS
  • TABLE 26 STATUS OF PAN-CANCER NEXT GENERATION DIAGNOSTICS TESTS
  • TABLE 27 STATUS OF PROSTATE CANCER NEXT GENERATION DIAGNOSTICS TESTS
  • TABLE 28 STATUS OF THYROID CANCER NEXT GENERATION DIAGNOSTICS TESTS
  • TABLE 29 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES
  • TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET
  • TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS
  • TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014
  • TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014
  • TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS
  • TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES
  • TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES
  • TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES
  • TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES
  • TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY
  • TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES
  • TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES
  • TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES
  • TABLE 43 CHINA'S BIOCHIP INDUSTRY
  • TABLE 44 LOAC COMPETITOR LANDSCAPE
  • TABLE 45 ANTIBODY REAGENT MARKET, 2014 (%)
  • TABLE 46 MULTIPLEX PROTEIN IN-VITRO DIAGNOSTICS COMPANIES
  • TABLE 47 DRIED BLOOD SPOT PROTEOMICS INDUSTRY
  • TABLE 48 SINGLE CELL PROTEOMICS INDUSTRY
  • TABLE 49 PROTEOMIC INDUSTRY GROWTH DRIVING FORCES
  • TABLE 50 GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2019 ($ MILLIONS)
  • TABLE 51 GLOBAL PROTEOMIC RESEARCH MARKET BY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • TABLE 52 GLOBAL PROTEOMIC RESEARCH MARKET BY BIOCHIP PLATFORM, THROUGH 2019 ($ MILLIONS)
  • TABLE 53 GLOBAL PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT PRODUCT MARKET BY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • TABLE 54 GLOBAL PROTEOMIC BIOCHIP DRUG DISCOVERY AND DEVELOPMENT MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 55 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY PLATFORM, THROUGH 2019 ($ MILLIONS)
  • TABLE 56 GLOBAL BIOCHIP DIAGNOSTIC MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 57 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY DISEASE TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 58 STATUS OF PROTEOMIC-BASED DIAGNOSTICS FOR DIABETES, NEUROLOGICAL, AUTOIMMUNE, INFECTIOUS DISEASE, HLA TYPING, AND CARDIOVASCULAR DISEASE APPLICATIONS
  • TABLE 59 SEPSIS DIAGNOSTICS INDUSTRY
  • TABLE 60 GLOBAL PROTEOMIC CANCER DIAGNOSTIC PRODUCT MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 61 GLOBAL MASS SPECTROMETRY MARKET BY PRODUCT TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 62 GLOBAL MASS SPECTROMETRY MARKET BY END-USER INDUSTRY, THROUGH 2019 ($ MILLIONS)
  • TABLE 63 MRM-MS VERSUS MALDI MS IN CLINICAL APPLICATIONS
  • TABLE 64 MS CLINICAL INDUSTRY
  • TABLE 65 PHOSPHOPROTEOMICS PLATFORMS FOR CANCER APPLICATIONS
  • TABLE 66 GLOBAL MASS SPECTROMETRY INSTRUMENT PROTEOMICS MARKET BY TECHNIQUE, THROUGH 2019 ($ MILLIONS)
  • TABLE 67 GLOBAL MASS SPECTROMETRY CONSUMABLE MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 68 GLOBAL PROTEOMIC BIOCHIP MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 69 GLOBAL PROTEOMIC ARRAY MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 70 GLOBAL PROTEOMIC BIOCHIP MARKET BY END-USER INDUSTRY, THROUGH 2019 ($ MILLIONS)
  • TABLE 71 GLOBAL PROTEOMIC ARRAY MARKET BY END-USER INDUSTRY, THROUGH 2019 ($ MILLIONS)
  • TABLE 72 GLOBAL PROTEOMIC LOAC MARKET BY END-USER INDUSTRY, THROUGH 2019 ($ MILLIONS)
  • TABLE 73 GLOBAL PROTEOMIC MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 74 GLOBAL PROTEOMIC DIAGNOSTIC MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 75 ARRAY-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014
  • TABLE 76 LAB-ON-A-CHIP-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014
  • TABLE 77 MASS SPECTROMETRY-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014 (NO. OF PATENTS)
  • TABLE 78 APPLICATIONS FOR Y2H AND YCHEMH PROTEOMICS PLATFORMS
  • TABLE 79 SOMALOGIC PROTEOMIC METHODS
  • TABLE 80 PERSONALIZED PROTEOMICS COMPANIES
  • TABLE 81 UNIVERSAL BIOSENSORS DIAGNOSTIC PIPELINE

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL PROTEOMIC MARKET BY END-USER INDUSTRY, 2013-2019 ($ MILLIONS)
  • FIGURE 1 MASS SPECTROMETRY GENERALIZED WORKFLOW SCHEMATIC
  • FIGURE 2 PROTEOMIC BIOCHIP AND ARRAY FORMATS
  • FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW
Back to Top